Arcus Biosciences, Inc. (RCUS), Tuesday announced results from part 1 of ARC-10, evaluating the effects of the combination of Domvanalimab and Zimberelimab versus Zimberelimab or chemotherapy.
The randomized, open-label, three-arm study was conducted in patients with front-line locally advanced or metastatic squamous or non-squamous non-small cell lung cancer with PD-L1 tumor proportion score =50 percent without the presence of any tumor genomic aberration or driver mutation.
The combination drug showed greater progression-free survival, overall survival, and objective response rate compared with those of Zimberelimab or chemotherapy.
Also, the treatment-related adverse events leading to treatment discontinuation were low for the combination of Domvanalimab and Zimberelimab compared to chemotherapy.
Currently, Arcus's stock is trading at $15.32, down 1.54 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Health News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.